Stock listing
Revelation Biosciences, Inc.
Selected listing: REVB · NASDAQ · USD · US
Revelation Biosciences, Inc. (NASDAQ:REVB), Health Technology. Latest release Aug 19, 2026: Revelation Biosciences Selects Avance Clinical as CRO for Phase…
- Ticker
- NASDAQ:REVB
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
About Revelation Biosciences, Inc.
The company focuses on developing innovative therapies and solutions in the biosciences sector. As a publicly traded entity, it operates within the American market, providing investors with opportunities to engage in its growth and development.
Latest news from Revelation Biosciences, Inc.
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
August 19, 2026
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
August 6, 2026
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
August 3, 2026
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 21, 2026
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
July 10, 2026
Research Revelation Biosciences, Inc.
Revelation Biosciences, Inc. company profile
View the public company page for Revelation Biosciences, Inc. on 6ix.
Revelation Biosciences, Inc. news
Read company news and market updates connected to Revelation Biosciences, Inc..
Revelation Biosciences, Inc. investor events
Find investor webinars, events, and replay context for Revelation Biosciences, Inc..